PATHOLOGY PRESENTS

“Loss of CEACAM1 links non-alcoholic fatty liver disease to atherosclerosis”

Sonia Najjar, PhD

OHF John J. Kopchick PhD, Endowed Eminent Research Chair
Heritage College of Osteopathic Medicine

Wednesday, March 18th, 2020
4:30pm-5:30pm
HSB T-739

Student Host: Jenny Brown

Non-alcoholic fatty liver disease (NAFLD) and its progressive form Non-alcoholic steatohepatitis (NASH) are reaching an epidemic growth. If uncontrolled, NASH can progress to liver adenocarcinoma that necessitates liver transplant. To date, there is no FDA-approved drug against NAFLD/NASH, owing largely to our limited understanding of its underlying mechanisms. Moreover, NASH is linked strongly to atherosclerosis and cardiovascular abnormalities of the metabolic syndrome. The Najjar laboratory has focused on delineating a unifying mechanism of these cardiometabolic abnormalities with an overarching goal to gain a thorough insight on their pathogenesis and develop more effective therapies.

To request disability accommodations, contact the Office of the ADA Coordinator at least ten days in advance of the event: 543-6450 (voice); 543-6452 (TDD); 685-3885 (fax); access@u.washington.edu (e-mail).